MobiHealth News March 20, 2025
The company will use the funds to expand the U.S. market and advance its AI-driven technology into new areas.
Brainomix, a company offering AI-powered imaging tools for stroke and lung fibrosis, announced the completion of an $18 million Series C investment round.
The round was co-led by existing investors Parkwalk Advisors and the Boehringer Ingelheim Venture Fund.
New investor Hostplus via the IP Group Hostplus Innovation Fund and LifeSci Capital participated in the round.
WHAT IT DOES
Brainomix is an AI-powered software platform that enables precision medicine for better treatment decisions in stroke and lung fibrosis. The company’s Brainomix 360 e-Lung technology predicts the progression of stroke and lung fibrosis.
The company’s Brainomix 360 Stroke automates imaging biomarkers aimed at...
Today's Sponsors
Today's Sponsor